How much revenue does Apogee Therapeutics make?

Apogee Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.

What companies are similar to Apogee Therapeutics?

Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Medy-Tox Inc. (086900.KQ), Galderma Group N (GALD.SW), TWi Biotechnology, Inc. (6610.TWO), Krystal Biotech, Inc. (KRYS).

Apogee Therapeutics, Inc. (APGE) Stock

FinancialsShareholders

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chro...

At a glance

Apogee Therapeutics reported revenue of $0 for fiscal year 2025, and net income of -$255.84 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.